Post-PCAC Telehealth Peptide Competitive Landscape Synthesis: Hims & Hers Health (NYSE: HIMS) Q2 $753M Revenue Reported Monday After Market Close, LifeMD (NASDAQ: LFMD) Approximately 310,000 Active Telehealth Subscribers Per Recent Investor Materials, Ro and Henry Meds Rounding Out the Large-Player Set; Alliance for Pharmacy Compounding, Empower Pharmacy, and American Institute for Compounded Therapeutics Were Among Key Institutional Commenters Supporting the July 23-24, 2026 PCAC 6-of-7 Vote Recommendation That Set Up the Prospective Legal-Compounding Channel for BPC-157, KPV, TB-500, MOTS-c, Semax, and Epitalon Once FDA Rulemaking Completes (Typically 12-24 Months)
The post-PCAC telehealth peptide competitive landscape continues to shape investor attention. Hims & Hers Health (NYSE: HIMS) Q2 2026 revenue of $753.2 million (+38% YoY) reported Monday August 10 after market close positions Hims as the largest US telehealth peptide-strategy sponsor. LifeMD (NASDAQ: LFMD) has approximately 310,000 active telehealth subscribers per recent investor materials, with 2025 revenue guided at $265-275 million. Ro and Henry Meds round out the large-player telehealth set. Key institutional commenters supporting the July 23-24, 2026 FDA Pharmacy Compounding Advisory Committee (PCAC) 6-of-7 vote recommendation included the Alliance for Pharmacy Compounding, Empower Pharmacy, American Institute for Compounded Therapeutics, Texas Pharmacy Association, real-world data platform Peptide AI, and the American Academy of Peptide Medicine. The July 23-24 vote recommendation (BPC-157, KPV, TB-500, MOTS-c, Semax, Epitalon approved 6 of 7; Emideltide/DSIP rejected) sets up the prospective legal compounding channel once FDA rulemaking completes (typically 12-24 months per PCAC-recommended substance). Enforcement context: the FDA issued 40+ warning letters and 100+ cease-and-desist notices to compounders and telehealth companies in 2024-2025 (the single largest enforcement action in compounding-pharmacy regulation history), and by March 2026 the FDA had sent warning letters to 30 additional telehealth companies with total enforcement actions exceeding 125 warning and untitled letters. The February 2027 PCAC second-peptide meeting (LL-37, GHK-Cu, dihexa acetate, melanotan II, PEG-MGF) will further shape the compounding landscape.